KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Gains from Investment Securities (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Gains from Investment Securities data on record, last reported at -$17.6 million in Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 1607.78% year-over-year to -$17.6 million; the TTM value through Dec 2025 reached -$18.7 million, down 1480.73%, while the annual FY2025 figure was -$18.7 million, 2100.0% down from the prior year.
  • Gains from Investment Securities reached -$17.6 million in Q3 2025 per PACB's latest filing, up from -$30.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $29.6 million in Q1 2025 and bottomed at -$30.7 million in Q2 2025.
  • Average Gains from Investment Securities over 5 years is -$42944.4, with a median of $102000.0 recorded in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 7444.91% in 2025, down 1607.78% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $304000.0 in 2021, then soared by 1412.5% to $4.6 million in 2022, then tumbled by 108.53% to -$392000.0 in 2023, then plummeted by 397.45% to -$2.0 million in 2024, then crashed by 804.67% to -$17.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$17.6 million in Q3 2025, -$30.7 million in Q2 2025, and $29.6 million in Q1 2025.